Neoadjuvant therapy for pancreatic cancer / 中华消化外科杂志

ABSTRACT

Pancreatic cancer has a extremely high malignancy,and simple surgical resection can not significantly improve the long-term survival rate of patients.Neoadjuvant therapy is the preoperative chemotherapy or combined chemo radiotherapy,which is used for downstaging tumors,eliminating subclinical metastases,transforming unresectable into resectable tumors,and improving the R0 resection rate of pancreatic cancer,thus ultimately improving the efficacy of pancreatic cancer.At present,neoadjuvant therapy has gradually become the mainstream treatment for locally advanced and borderline resectable pancreatic cancer.New adjuvant therapy for resectable pancreatic cancer has been supported by some high-quality clinical research data,which will become a hot topic in clinical research.The author believes that there will be more clinical research data to help individualized neoadjuvant treatment selection,accurate efficacy evaluation and prognosis judgement,and ultimately improve the efficacy of patients with pancreatic cancer.